CAR T-cell therapy for AIHA after 3 failed treatments
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have autoimmune hemolytic anemia (AIHA) that has not improved after trying at least 3 different treatments.
- A blood test shows your B cells have a marker called CD19 or BCMA.
- You are generally healthy enough for this treatment (no active infections, serious heart problems, or other cancers in the last 5 years).
- If you could become pregnant, you must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This study tests a new treatment called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not improved with other treatments. It aims to see if this therapy can help control the disease and improve blood counts.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.